EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Autoimmune Hemolytic Anemias: Challenges in Diagnosis and Therapy

Wilma Barcellini, Bruno Fattizzo

Transfusion Medicine and Hemotherapy · 27.08.2024 · 51 (5) · 321-331

DOI: 10.1159/000540475 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Transfusion Medicine and Hemotherapy, online erschienen am 27.08.2024. Verfasst von Wilma Barcellini und 1 weiteren Autor:innen. Beteiligte Einrichtung: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Autoimmune hemolytic anemia (AIHA) is a rare disease due to increased destruction of erythrocytes by autoantibodies, with or without complement activation. Summary: AIHA is usually classified in warm AIHA (wAIHA) and cold agglutinin disease (CAD), based on isotype and thermal amplitude of the autoantibody. The direct antiglobulin test (DAT) or Coombs test is the cornerstone of AIHA diagnosis, as it is positive with anti-IgG in wAIHA, and with anti-C3d/IgM antisera plus high titer cold agglutinins in CAD. Therapy is quite different, as steroids and rituximab are effective in the former, but have a lower response rate and duration in the latter. Splenectomy, which is still a good option for young/fit wAIHA, is contraindicated in CAD, and classic immunosuppressants are moving to further lines. Several new drugs are increasingly used or are in trials for relapsed/refractory AIHAs, including B-cell (parsaclisib, ibrutinib, rilzabrutinib), and plasma cell target therapies (bortezomib, daratumumab), bispecific agents (ianalumab, obexelimab, povetacicept), neonatal Fc receptor blockers (nipocalimab), and complement inhibitors (sutimlimab, riliprubart, pegcetacoplan, iptacopan). Clinically, AIHAs are highly heterogeneous, from mild/compensated to life-threatening/fulminant, and may be primary or associated with infections, neoplasms, autoimmune diseases, transplants, immunodeficiencies, and drugs. Along with all these variables, there are rare forms like mixed (wAIHA plus CAD), atypical (IgA or warm IgM driven), and DAT negative, where the diagnosis and clinical management are particularly challenging. Key Messages: This article covers the classic clinical features, diagnosis, and therapy of wAIHA and CAD, and focuses, with the support of clinical vignettes, on difficult diagnosis and refractory/relapsing cases requiring novel therapies.

Schlagwörter

Stichwörter der Autor:innen

Cold agglutinin diseaseComplement systemDirect anti-globulin testInfectionRituximabThrombosisWarm autoimmune hemolytic anemia

Autor:innen und Institutionen

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

Zitieren

APA

Barcellini, W., & Fattizzo, B. (2024). Autoimmune Hemolytic Anemias: Challenges in Diagnosis and Therapy. Transfusion Medicine and Hemotherapy, 51(5), 321-331. https://doi.org/10.1159/000540475

Vancouver

Barcellini W, Fattizzo B. Autoimmune Hemolytic Anemias: Challenges in Diagnosis and Therapy. Transfusion Medicine and Hemotherapy. 2024;51(5):321-331. doi:10.1159/000540475

BibTeX
@article{Barcellini2024,
  author = {Barcellini, Wilma and Fattizzo, Bruno},
  title = {Autoimmune Hemolytic Anemias: Challenges in Diagnosis and Therapy},
  journal = {Transfusion Medicine and Hemotherapy},
  year = {2024},
  volume = {51},
  number = {5},
  pages = {321--331},
  doi = {10.1159/000540475}
}
Kostenlos starten →